|
Jan 9
|
Factbox-What does the Gotham City report say about Grifols?
|
|
Jan 9
|
Grifols Denies Gotham Claims as Short Seller Triggers 26% Rout
|
|
Jan 9
|
Factbox-What is Grifols and why have its shares slumped?
|
|
Jan 9
|
Grifols Stock Tanks, Short Seller Alleges Profit Manipulation, Concerning Financial Health
|
|
Jan 9
|
Grifols Sinks as Short Seller Gotham Criticizes Accounting
|
|
Jan 9
|
Spain's Grifols slumps after short-seller accuses healthcare group of fraud
|
|
Jan 9
|
Gotham City accounting queries wipe $3 billion off Grifols value
|
|
Dec 29
|
Uber and Lyft downgraded: Wall Street's top analyst calls
|
|
Dec 27
|
GRFS or ZTS: Which Is the Better Value Stock Right Now?
|
|
Dec 7
|
GRFS vs. ZTS: Which Stock Is the Better Value Option?
|
|
Nov 6
|
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023
|
|
Nov 3
|
Grifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Call Transcript
|
|
Sep 14
|
GRFS or STVN: Which Is the Better Value Stock Right Now?
|
|
Jul 21
|
Should Value Investors Buy Grifols (GRFS) Stock?
|
|
Jul 20
|
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
|
|
Jul 18
|
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
|